Lupin receives EIR from USFDA for Tarapur facility

27 Nov 2018 Evaluate

Lupin has received the Establishment Inspection Report (EIR) on the completion of an inspection by the United States Food & Drug Administration (USFDA) at its facility in Tarapur, Maharashtra. The inspection conducted between August 27 and August 31, 2018 concluded with one inspectional observation.

Founded in 1992, the Tarapur facility is a state-of-the-art unit for manufacturing Active Pharmaceuticals Ingredients (API), both fermentation-based and synthetic.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×